Tanvex Biopharma Stock Fundamentals
| 6541 Stock | TWD 41.05 0.95 2.26% |
Tanvex BioPharma fundamentals help investors to digest information that contributes to Tanvex BioPharma's financial success or failures. It also enables traders to predict the movement of Tanvex Stock. The fundamental analysis module provides a way to measure Tanvex BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tanvex BioPharma stock.
Tanvex |
Tanvex BioPharma Company Shares Outstanding Analysis
Tanvex BioPharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Tanvex BioPharma Shares Outstanding | 352.74 M |
Most of Tanvex BioPharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tanvex BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Tanvex BioPharma has 352.74 M of shares currently outstending. This is 95.39% higher than that of the Healthcare sector and 230.11% higher than that of the Biotechnology industry. The shares outstanding for all Taiwan stocks is 38.31% higher than that of the company.
Tanvex BioPharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tanvex BioPharma's current stock value. Our valuation model uses many indicators to compare Tanvex BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tanvex BioPharma competition to find correlations between indicators driving Tanvex BioPharma's intrinsic value. More Info.Tanvex BioPharma is rated fifth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tanvex BioPharma's earnings, one of the primary drivers of an investment's value.Tanvex Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tanvex BioPharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tanvex BioPharma could also be used in its relative valuation, which is a method of valuing Tanvex BioPharma by comparing valuation metrics of similar companies.Tanvex BioPharma is currently under evaluation in shares outstanding category among its peers.
Tanvex Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (76.42) % | |||
| Current Valuation | 14.19 B | |||
| Shares Outstanding | 352.74 M | |||
| Shares Owned By Insiders | 53.74 % | |||
| Shares Owned By Institutions | 4.30 % | |||
| Price To Book | 7.12 X | |||
| Price To Sales | 681.78 X | |||
| Revenue | 5.41 M | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (1.25 B) | |||
| Net Income | (1.54 B) | |||
| Cash And Equivalents | 1.65 B | |||
| Cash Per Share | 5.29 X | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 7.89 X | |||
| Book Value Per Share | 5.35 X | |||
| Cash Flow From Operations | (1.39 B) | |||
| Earnings Per Share | (4.35) X | |||
| Target Price | 52.4 | |||
| Number Of Employees | 23 | |||
| Beta | 0.67 | |||
| Market Capitalization | 17.11 B | |||
| Total Asset | 4.71 B | |||
| Net Asset | 4.71 B |
About Tanvex BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tanvex BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tanvex BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tanvex BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. TANVEX BIOPHARMA is traded on Taiwan Stock Exchange in Taiwan.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.